Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.
Medicure’s vision is to become a leading specialty pharmaceutical company that improves the lives of patients while delivering value for its shareholders. The Company’s current focus is in the area of acute cardiovascular care, a market served by the its commercial product, AGGRASTAT (tirofiban HCl). The Company is also looking to develop and acquire additional hospital products. To accomplish this, the Company is leveraging its historical expertise in clinical development as well as exploring acquisition opportunities with growth potential.
Medicure was established in 1997, and spent its first decade focused on research and development. In 2008, the Company began a transition to focus on its commercial, specialty pharmaceutical business. This new direction was solidified in October 2013 with the U.S. FDA approval of the new label for AGGRASTAT. The label change has provided a basis for the Company to grow sales and achieve profitability, and also to pursue development and acquisition opportunities.
Medicure’s board and management is committed to building value for its existing shareholder base and is patiently pursuing a long-term view to establishing the Company as a leading, international pharmaceutical company - one that is distinguished by its unique fit within the contemporary market.
Medicure Inc. is based in Winnipeg, Canada and publicly traded on the Toronto Stock Exchange Venture under the symbol MPH. Its subsidiaries include Medicure International, Inc. (Barbados), which owns the U.S. rights to AGGRASTAT, as well as two U.S. corporations, Medicure USA, Inc. and Medicure Pharma, Inc., which distributes the Company’s products in the United States. Medicure Inc. and Medicure USA have a minority interest and fixed option to acquire the holding companies of Apicore LLC and Apicore US LLC (collectively, Apicore). Apicore is a developer and manufacturer of specialty Active Pharmaceutical Ingredients (APIs) and generic products (ANDAs).
For more information About Medicure and the risks and uncertainties involved in its business, please refer to the most recent Management Discussion and Analysis and in the "Risk Factors" section of its most recent Form 20F.